Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioReference Laboratories and its GenPath Oncology business unit have launched solid tumor genotype test through its exclusive commercialization agreement with the Massachusetts General Hospital (MGH).
Subscribe to our email newsletter
The OnkoMatch test is designed for solid tumor cancers such as lung, breast, colon, pancreas, thyroid and skin.
The test will analyze 14 oncogenes, genes that drive cancer, across 68 mutational hot spots, from a single tissue specimen taken from the patient’s tumor.
Tumor genotyping through OnkoMatch will enable oncologists to match their patients with appropriate targeted therapy, either FDA approved or in a clinical trial setting.
BioReference president and CEO Marc Grodman said that through the commercialization agreement with MGH they have collaborated in key areas such as bioinformatics and clinical interpretation.